Sarepta Therapeutics (SRPT) Competitors

Sarepta Therapeutics (NASDAQ:SRPT) and CytomX Therapeutics (NASDAQ:CTMX) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, profitability, valuation, institutional ownership, earnings, media sentiment, risk and dividends.

Which has more volatility and risk, SRPT or CTMX?

Sarepta Therapeutics has a beta of 0.46, indicating that its share price is 54% less volatile than the S&P 500. Comparatively, CytomX Therapeutics has a beta of 2.13, indicating that its share price is 113% more volatile than the S&P 500.

Do analysts rate SRPT or CTMX?

Sarepta Therapeutics currently has a consensus price target of $44.17, suggesting a potential upside of 116.83%. CytomX Therapeutics has a consensus price target of $5.75, suggesting a potential upside of 224.86%. Given CytomX Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe CytomX Therapeutics is more favorable than Sarepta Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sarepta Therapeutics	5 Sell rating(s)	16 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.10
CytomX Therapeutics	0 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	3.00

Do insiders & institutionals hold more shares of SRPT or CTMX?

86.7% of Sarepta Therapeutics shares are owned by institutional investors. Comparatively, 67.8% of CytomX Therapeutics shares are owned by institutional investors. 7.6% of Sarepta Therapeutics shares are owned by insiders. Comparatively, 6.6% of CytomX Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Which has stronger earnings and valuation, SRPT or CTMX?

Sarepta Therapeutics has higher revenue and earnings than CytomX Therapeutics. Sarepta Therapeutics is trading at a lower price-to-earnings ratio than CytomX Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sarepta Therapeutics	$1.90B	1.05	$235.24M	-$0.87	-23.41
CytomX Therapeutics	$138.10M	1.03	$31.87M	$0.56	3.16

Is SRPT or CTMX more profitable?

CytomX Therapeutics has a net margin of 34.04% compared to Sarepta Therapeutics' net margin of -2.34%. CytomX Therapeutics' return on equity of 158.70% beat Sarepta Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sarepta Therapeutics	-2.34%	-1.03%	-0.37%
CytomX Therapeutics	34.04%	158.70%	36.04%

Does the media prefer SRPT or CTMX?

In the previous week, Sarepta Therapeutics had 40 more articles in the media than CytomX Therapeutics. MarketBeat recorded 56 mentions for Sarepta Therapeutics and 16 mentions for CytomX Therapeutics. Sarepta Therapeutics' average media sentiment score of 0.40 beat CytomX Therapeutics' score of 0.04 indicating that Sarepta Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Sarepta Therapeutics	10 Very Positive mention(s)	3 Positive mention(s)	36 Neutral mention(s)	3 Negative mention(s)	1 Very Negative mention(s)	Neutral
CytomX Therapeutics	0 Very Positive mention(s)	2 Positive mention(s)	6 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Sarepta Therapeutics and CytomX Therapeutics tied by winning 8 of the 16 factors compared between the two stocks.